$5.02 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 132 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 116.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | AERIE PHARMACEUTICALS INCnote 1.500%10/0 | $170,826,000 | +28.4% | 174,372,000 | +10.8% | 3.40% | +23.9% | |
| New | SAREPTA THERAPEUTICS INCdbcv 1.500%11/1 | $148,264,000 | – | 88,657,000 | +100.0% | 2.95% | – | |
| BIIB | New | BIOGEN INC | $88,110,000 | – | 330,000 | +100.0% | 1.75% | – |
| New | ALPHATEC HLDGS INCnote 0.750% 8/0 | $81,430,000 | – | 100,000,000 | +100.0% | 1.62% | – | |
| New | INTERCEPT PHARMACEUTICALS INnote 3.500% 2/1 | $81,098,000 | – | 78,500,000 | +100.0% | 1.61% | – | |
| Buy | ACCOLADE INCnote 0.500% 4/0 | $79,078,000 | +33.7% | 105,000,000 | +13.4% | 1.57% | +29.0% | |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $73,456,000 | +108.6% | 4,855,005 | +3.4% | 1.46% | +101.4% |
| CPRX | New | CATALYST PHARMACEUTICALS INC | $62,816,000 | – | 4,896,000 | +100.0% | 1.25% | – |
| LUNG | Buy | PULMONX CORP | $61,990,000 | +21.5% | 3,720,901 | +7.4% | 1.23% | +17.3% |
| RVMD | Buy | REVOLUTION MEDICINES INC | $57,022,000 | +228.1% | 2,891,587 | +224.3% | 1.14% | +217.0% |
| LRMR | Buy | LARIMAR THERAPEUTICS INC | $54,212,000 | +374.4% | 16,941,357 | +190.6% | 1.08% | +357.2% |
| MRUS | Buy | MERUS N V | $50,507,000 | +12.3% | 2,521,553 | +27.0% | 1.00% | +8.4% |
| New | NANOSTRING TECHNOLOGIES INCnote 2.625% 3/0 | $48,669,000 | – | 57,604,000 | +100.0% | 0.97% | – | |
| Buy | HILLEVAX INC | $45,344,000 | +58.5% | 2,653,231 | +1.3% | 0.90% | +53.1% | |
| EOLS | Buy | EVOLUS INC | $43,390,000 | +3.0% | 5,390,103 | +48.4% | 0.86% | -0.6% |
| ANAB | Buy | ANAPTYSBIO INC | $37,413,000 | +138.7% | 1,466,600 | +90.0% | 0.74% | +130.7% |
| BKD | Buy | BROOKDALE SR LIVING INC | $37,117,000 | -4.9% | 8,692,561 | +1.2% | 0.74% | -8.2% |
| AMED | Buy | AMEDISYS INC | $34,822,000 | +66.5% | 359,765 | +80.8% | 0.69% | +60.8% |
| PHR | Buy | PHREESIA INC | $34,602,000 | +61.4% | 1,358,000 | +58.4% | 0.69% | +55.9% |
| BLU | Buy | BELLUS HEALTH INC NEW | $32,535,000 | +42.4% | 3,081,000 | +24.6% | 0.65% | +37.6% |
| PHAT | New | PHATHOM PHARMACEUTICALS INC | $26,757,000 | – | 2,414,897 | +100.0% | 0.53% | – |
| IDYA | New | IDEAYA BIOSCIENCES INC | $26,015,000 | – | 1,743,628 | +100.0% | 0.52% | – |
| VERV | New | VERVE THERAPEUTICS INC | $25,763,000 | – | 750,000 | +100.0% | 0.51% | – |
| Buy | HEALTH CATALYST INCnote 2.500% 4/1 | $25,533,000 | +89.8% | 30,000,000 | +100.0% | 0.51% | +83.4% | |
| SWTX | New | SPRINGWORKS THERAPEUTICS INC | $23,309,000 | – | 816,994 | +100.0% | 0.46% | – |
| ATEC | Buy | ALPHATEC HLDGS INC | $22,137,000 | +39.8% | 2,532,792 | +4.6% | 0.44% | +34.9% |
| New | ENHABIT INC | $20,418,000 | – | 1,454,279 | +100.0% | 0.41% | – | |
| New | VIGIL NEUROSCIENCE INC | $17,951,000 | – | 2,054,794 | +100.0% | 0.36% | – | |
| ISEE | New | IVERIC BIO INCcall | $17,940,000 | – | 1,000,000 | +100.0% | 0.36% | – |
| OMIC | Buy | SINGULAR GENOMICS SYSTEMS IN | $17,695,000 | -26.9% | 7,078,019 | +11.7% | 0.35% | -29.5% |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $13,885,000 | – | 870,000 | +100.0% | 0.28% | – |
| KRYS | New | KRYSTAL BIOTECH INC | $12,198,000 | – | 175,000 | +100.0% | 0.24% | – |
| PACB | New | PACIFIC BIOSCIENCES CALIF IN | $11,732,000 | – | 2,021,000 | +100.0% | 0.23% | – |
| ADCT | New | ADC THERAPEUTICS SA | $11,521,000 | – | 2,390,297 | +100.0% | 0.23% | – |
| VCEL | New | VERICEL CORP | $11,251,000 | – | 484,947 | +100.0% | 0.22% | – |
| TERN | New | TERNS PHARMACEUTICALS INC | $10,955,000 | – | 1,860,000 | +100.0% | 0.22% | – |
| PNT | New | POINT BIOPHARMA GLOBAL INC | $7,730,000 | – | 1,000,000 | +100.0% | 0.15% | – |
| AFIB | Buy | ACUTUS MED INC | $2,333,000 | -21.3% | 2,651,667 | +0.1% | 0.05% | -24.6% |
| NUVB | New | NUVATION BIO INC | $550,000 | – | 245,360 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.